Shanghai Pharmaceuticals (SHA:601607) received supplementary drug approval from China's National Medical Products Administration for its promethazine hydrochloride injection, according to a Tuesday disclosure to the Shanghai Stock Exchange.
The drug is indicated for skin and mucus membrane allergies, as well as motion sickness, and as an adjunct treatment before and after surgery.